Pasithea Return On Assets from 2010 to 2024

KTTAW Stock  USD 0.02  0  8.97%   
Pasithea Therapeutics Return On Assets yearly trend continues to be fairly stable with very little volatility. Return On Assets will likely drop to -0.64 in 2024. Return On Assets is a profitability ratio that indicates the percentage of profit Pasithea Therapeutics Corp earns in relation to its overall resources. It is calculated by dividing net income by total assets. View All Fundamentals
 
Return On Assets  
First Reported
2010-12-31
Previous Quarter
(0.61)
Current Value
(0.64)
Quarterly Volatility
0.16872751
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pasithea Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pasithea Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 680.9 K, Other Operating Expenses of 9.9 M or Total Operating Expenses of 9.8 M, as well as many indicators such as Price To Sales Ratio of 36.39, Dividend Yield of 0.0 or PTB Ratio of 0.38. Pasithea financial statements analysis is a perfect complement when working with Pasithea Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Pasithea Therapeutics Correlation against competitors.

Latest Pasithea Therapeutics' Return On Assets Growth Pattern

Below is the plot of the Return On Assets of Pasithea Therapeutics Corp over the last few years. It is a profitability ratio that indicates the percentage of profit a company earns in relation to its overall resources. It is calculated by dividing net income by total assets. Pasithea Therapeutics' Return On Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pasithea Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Return On Assets10 Years Trend
Slightly volatile
   Return On Assets   
       Timeline  

Pasithea Return On Assets Regression Statistics

Arithmetic Mean(0.23)
Coefficient Of Variation(74.46)
Mean Deviation0.11
Median(0.17)
Standard Deviation0.17
Sample Variance0.03
Range0.5992
R-Value(0.58)
Mean Square Error0.02
R-Squared0.34
Significance0.02
Slope(0.02)
Total Sum of Squares0.40

Pasithea Return On Assets History

2024 -0.64
2023 -0.61
2022 -0.29
2021 -0.0408

About Pasithea Therapeutics Financial Statements

Pasithea Therapeutics investors use historical fundamental indicators, such as Pasithea Therapeutics' Return On Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pasithea Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Assets(0.61)(0.64)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pasithea Stock Analysis

When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.